Review: Helicobacter pylori infection in children

Ji-Hyun Seo1, Kristen Bortolin2, Nicola L Jones3

  • 1Department of Pediatrics, Gyeongsang National Institute of Health Sciences, Gyeongsang National University College of Medicine, Jinju, Korea.

Helicobacter
|September 12, 2020
PubMed

Insights

Helicobacter pylori infection in children presents unique challenges, with decreasing prevalence but rising antibiotic resistance. Research is crucial for effective pediatric management and understanding its impact on immunity and the microbiome.

Area of Science:

  • Pediatric Gastroenterology
  • Infectious Diseases
  • Microbiology

Background:

  • Helicobacter pylori infection in children and adolescents has distinct epidemiological and clinical features compared to adults.
  • Limited treatment options and increasing antibiotic resistance in pediatric populations necessitate further research.
  • Understanding H. pylori pathogenesis in children is vital for optimal disease management.

Purpose of the Study:

  • To review recent literature (April 2019-March 2020) on Helicobacter pylori infection in children and adolescents.
  • To summarize findings on H. pylori epidemiology, host responses, and disease manifestations in the pediatric population.
  • To highlight current research trends, including pathogenesis, microbiome interactions, and diagnostic recommendations.

Main Methods:

  • Systematic review of publications from April 2019 to March 2020.
  • Analysis of studies investigating H. pylori prevalence, immune responses, and gut microbiome.
  • Evaluation of research on diagnostic strategies and treatment outcomes in pediatric H. pylori infection.

Main Results:

  • Recent studies indicate a declining prevalence of H. pylori infection in pediatric populations, mirroring adult trends.
  • Research explored serum immune responses and a potential inverse relationship between H. pylori infection and allergies.
  • The impact of H. pylori and associated inflammation on the gut microbiome was a significant area of investigation.

Conclusions:

  • Endoscopy-based testing is recommended for symptom evaluation, with noninvasive tests reserved for post-eradication follow-up.
  • Continued research is essential to address the challenges of H. pylori management in children, including antibiotic resistance.
  • The review underscores the importance of understanding H. pylori's complex interactions with the pediatric host and microbiome.

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
840
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
397
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
942
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
600
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
979
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
300